Biogen faced several pipeline setbacks in 2024, including programs for ALS, tremor, and Angelman syndrome. Two promising late-stage programs, felzartamab entering Phase 3 trials for IgA ...

Still, a lot is riding on this Alzheimer's treatment and Biogen's other pipeline candidates, and that equals risk. Considering this, I was concerned about Biogen -- until I heard 11 words from its ...

Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Recent business development deals have focused on enhancing the company’s late-stage pipeline, including the company’s latest collaboration with Stoke Therapeutics. In parallel, Biogen’s ...

While detailed results are yet to be presented at a forthcoming medical congress, the study's success marks a significant milestone for Biogen's pipeline. RBC Capital notes that while the positive ...

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

We plan to further advance the launch of Leqembi, together with Eisai, and continue to bolster innovation with the development of the other assets in our pipeline,” Biogen CEO and President ...

Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline hasn’t gotten the message yet. The Cambridge, Massachusetts ...

Biogen said Wednesday it will acquire a California biotech that specializes in diseases of the immune system for $1.15 billion upfront as the Cambridge drugmaker seeks to bolster its pipeline of ...

Biogen Inc. agreed to acquire Human Immunology Biosciences Inc. for as much as $1.8 billion in a deal aimed at bolstering the biotechnology giant’s pipeline of immune disease treatments.

Jefferies downgraded Biogen from Buy to Hold, setting a new price target of $180, down from $250. Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition.